Glaukos COO shares product updates, 2021 pipeline

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

Related Videos

Related Content

Advertisement

November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

November 18th 2024

Long-term blood pressure variability and visual field progression in glaucoma

November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

October 30th 2024

AI-related innovations for laser cataract technology mark a milestone in history of device

October 25th 2024

A history of the femtosecond laser in the United States and Europe

Related Content

Advertisement

November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

November 18th 2024

Long-term blood pressure variability and visual field progression in glaucoma

November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

October 30th 2024

AI-related innovations for laser cataract technology mark a milestone in history of device

October 25th 2024

A history of the femtosecond laser in the United States and Europe